menu
    • menu
    [{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"ABBV-CLS-579","moa":"PTPN2","graph1":"Oncology","graph2":"Phase I","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calico Life Sciences \/ AbbVie","highestDevelopmentStatusID":"6","companyTruncated":"Calico Life Sciences \/ AbbVie"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ABBV-CLS-7262","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Calico Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Calico Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ABBV-CLS-484","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Calico Life Sciences \/ Calico Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Calico Life Sciences \/ Calico Life Sciences"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fosigotifator","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Calico Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Calico Life Sciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Calico Life Sciences

    Menu

    Calico Life Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Calico Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Calico Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosigotifator

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Calico Announces Fosigotifator Selected for FDA Pilot Program for White Matter Disease

                            Details : ABBV-CLS-7262 (fosigotifator) is an eIF2B activator, a factor that is essential for protein synthesis and a key regulator of the ISR. It is being investigated for vanishing white matter disease.

                            Brand Name : ABBV-CLS-7262

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 07, 2024

                            Lead Product(s) : Fosigotifator

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Calico Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Calico Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-CLS-484,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : AbbVie Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhib...

                            Details : ABBV-CLS-484 is the first active-site phosphatase inhibitor to enter clinical evaluation as a cancer therapy and is currently in an AbbVie and Calico-led Phase 1 clinical trial in solid tumors.

                            Brand Name : ABBV-CLS-484

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 04, 2023

                            Lead Product(s) : ABBV-CLS-484,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : AbbVie Inc

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Calico Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Calico Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-CLS-7262

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating ABBV-CLS-7262 for...

                            Details : ABBV-CLS-7262 is an eIF2B activator which targets eIF2B, a guanine nucleotide exchange factor that is essential for protein synthesis and a key regulator of the ISR. It is being investigated for vanishing white matter disease.

                            Brand Name : ABBV-CLS-7262

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 26, 2023

                            Lead Product(s) : ABBV-CLS-7262

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Calico Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Calico Life Sciences

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-CLS-579

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related Diseases

                            Details : ABBV 579 is an IO asset, it is being studied in participants with locally advanced or metastatic tumors. As part of the collaboration, Calico pursues discovery-stage research and development utilizing state-of-the-art technology and advanced computing ca...

                            Brand Name : ABBV 579

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 27, 2021

                            Lead Product(s) : ABBV-CLS-579

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth